• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·CELZ
Share

Creative Medical Technology Holdings, Inc. Stocks

$ 0.84Last Updated 22.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 2.23M

$ 0.84
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

26.06.2026 15:38

Morning in New York: Indices Searching for Direction

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.07.2026 07:00

Reddit shares fell 8% following reports of a possible breakup of its AI partnership with Google

23.07.2026 05:24

Samsung Unveiled New Foldable Smartphones Ahead of Apple's Expected Entry into This Market

23.07.2026 04:20

The Houthis claimed to have attacked two oil tankers. The price of Brent crude surpassed $95.

23.07.2026 03:30

IBM confirmed the weak results that spooked the market. What does the company expect now?

23.07.2026 01:35

Revenue from Google's cloud business jumped 82%. The growth rate once again surprised the market.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026